We review an emerging microfluidics-based toolkit for single-cell functional proteomics. Functional proteins include, but are not limited to, the secreted signaling proteins that can reflect the biological behaviors of immune cells or the intracellular phosphoproteins associated with growth factor-stimulated signaling networks. Advantages of the microfluidics platforms are multiple. First, 20 or more functional proteins may be assayed simultaneously from statistical numbers of single cells. Second, cell behaviors (e.g., motility) may be correlated with protein assays. Third, extensions to quantized cell populations can permit measurements of cell-cell interactions. Fourth, rare cells can be functionally identified and then separated for further analysis or culturing. Finally, certain assay types can provide a conduit between biology and the physicochemical laws. We discuss the history and challenges of the field then review design concepts and uses of the microchip platforms that have been reported, with an eye toward biomedical applications. We then look to the future of the field.
INTRODUCTION
Over the past 25 years, microfluidic techniques (1) have emerged for the manipulation, sorting, and analysis of small biological samples, ranging from microliters of blood (2) to single cells (3, 4) . On-chip assays range from cell counting to molecular measurements, with applications that span broadly across the fields of biology and biomedicine. Many of these microchip tools have been extensively reviewed in the recent literature (5) (6) (7) (8) (9) (10) (11) . One of the newer technologies to emerge, and to be adapted to microchip formats, is single-cell functional proteomics. Functional proteins include the secreted cytokines, chemokines, proteases, and granulocytes that are commonly associated with immune cell function (12) but are also observed for other cell types. Functional proteins also include catalytically active (e.g., phosphorylated) kinases and associated effector proteins. This protein class comprises the intracellular signaling cascades (13) , which are often hyperactivated in cancer cells and are consequently targeted by anticancer therapies (14) . In their active states, such proteins have functional consequences that can be associated with the various hallmarks of cancer (15, 16) . The kinetics, abundances, and statistical distributions of functional proteins often set them apart from their nonfunctional counterparts. Thus, we begin in Section 2 with a discussion on a few representative examples of functional proteins, with an eye toward identifying those practical issues associated with single-cell assays.
The first reports of microchip platforms for single-cell functional proteomics appeared just within the past decade (17) (18) (19) (20) . However, the technology has evolved rapidly such that several clinically relevant and uniquely enabled applications have been reported. This suggests that, in the near future, at least some of these platforms will emerge as clinical tools for helping guide patient care. This rapid advance is due, in large part, to the long history of single-cell proteomics, which originated with techniques such as enzyme-linked immunosorbent spot (ELISpot) (21) and a host of cytometry methods. These techniques, which continue to serve as the gold standard for most single-cell proteomics assays, have guided the development of microchip-based technologies and have defined many of the important biological problems for investigation. In Section 3, we discuss some of that history and how it has influenced the development of the microchip platforms that are the subject of this review.
Microchip platforms for single-cell functional proteomics are based on either staining and imaging fixed cells (22) or putting live cells into small environments such as microbubbles (18) or microchambers (17, 20) for analysis. Each of these tools has distinct advantages and disadvantages, and a few have advanced toward being applied to addressing biomedical or clinical problems. Such applications, which imply significant scientific and engineering demands, have, in fact, served as technology drivers. We list those demands here. (a) Clinical applications imply single-use microchips, and thus the chips must be inexpensive to fabricate in at least moderate throughput, and in a highly reproducible manner. (b) In single-cell biology, statistical numbers of single cells (hundreds to thousands) must be analyzed for any given assay to generate a meaningful result (23) . (c) The proteomics (and other on-chip) assays must be robust and highly reproducible so that meaningful comparisons can be made between data sets collected across time points, patient samples, assay conditions, etc. (d ) For many problems, the relevant functional proteins are present at low abundance (10 2 -10 4 copies per cell). As a general rule, primary cells (direct from blood or tissue) contain significantly lower copy numbers of a given protein than do cultured cells. Thus, assay sensitivity is an important factor. Demands a and b largely describe engineering challenges, whereas demands c and d have mostly been addressed through a combination of surface chemistry approaches, coupled with advances in biomolecular labeling chemistries. In Section 4, we review the basic microfluidics platforms that have been reported. Because this is an analytical chemistry review, we emphasize quantitative measurement challenges and the engineering and surface chemistry solutions that are permitting those challenges to be addressed.
In Section 5, we highlight applications in which microchip-based single-cell proteomics tools are providing unique and useful advantages. One major area has been in the design of platforms that integrate different assays, such as measurements of cell motility (24) or immune cell activation (25) , correlated with functional proteomics assays from those same cells. A second area has been the ability to execute proteomics assays on quantized cell populations (i.e., 1, 2, 3. . .cells). These allow for a detailed analysis of specific cell-cell interactions (26, 27) . A third area has been with regards to the numbers and types of functional proteins that can be assayed per cell, as well as the level of absolute quantitation and sensitivity that can be achieved (28) . These capabilities open up new classes of systems for investigation. One such example involves the intracellular phosphoprotein signaling networks within cultured or primary cancer cells and the influence that targeted drugs can have on those networks (29, 30) .
Finally, in Section 6, we look toward the future. Some of our projections are straightforward, such as anticipating the increase in technical capabilities of the microchip platforms, including the integration of multiple omic-type assays on the same single cells. An area that is less defined, but very important, involves the development of a discovery-based single-cell proteomics approach. All existing single-cell proteomic methods rely on antibodies and as such are targeted toward measuring the levels of specific proteins, the identities of which are predetermined. An approach that can go beyond this limitation, perhaps involving mass spectrometry (31) , is a grand challenge of the field.
An area of single-cell functional proteomics that is omitted from this review is optical studies that utilize genetically modified cells as a means of generating in situ optical readouts of protein expression levels (see, e.g., 23, 32, 33) . Such investigations are revealing a rich biology that is highly relevant to many of the basic concepts stressed here.
DETECTING FUNCTIONAL PROTEINS FROM SINGLE CELLS: RELEVANT PARAMETERS
Functional proteins are often transient and low-abundance targets for measurement. They are typically generated, released, and/or activated following stimulation, and their production is often the end result of a series of stochastic events. In other words, they are the opposite of housekeeping proteins (such as actin) that are present in abundant and reasonably stable concentrations. Thus, experimental designs for capturing functional protein levels from single cells should take into account several factors, including (a) the expected number of copies that are produced by individual cells; (b) the stimulation conditions required to generate such proteins; (c) the expected variance in protein number as measured across many single cells; and (d ) the kinetics associated with that production, which can often compete with kinetics for the degradation of that same protein.
Additional relevant factors include the cell type and cell phenotype, whether the cell is from culture or is a primary cell, and the history of the cell prior to analysis. Providing a comprehensive description of these factors is well beyond the scope of this review. However, it is instructive to consider a few illustrative examples, which are provided in Table 1 . Listed in the table are three secreted proteins, including the cytokine tumor necrosis factor-α (TNF-α), the cytotoxic granule Granzyme B (GB), the secreted growth factor [vascular epithelial growth factor (VEGF)], a phosphorylated (p-) receptor tyrosine kinase (RTK) [epidermal growth factor receptor (EGFR)], and a cytoplasmic phosphokinase [p-extracellular signal-regulated kinase (ERK)].
The first entry is TNF-α, which, along with interferon-γ (IFN-γ), often provides a marker for immune cell activation. TNF-α is produced by numerous cell types following specific It requires cell stimulation. Tumor antigen-specific CD8 + T cells secrete from <10 1 to >10 5 copies over 12 h (Figure 1) . A secretion rate of 10 copies sec −1 was measured from influenza antigen-specific CD4 + T cells (25) . GB This is a serine protease (enzyme) present in cytotoxic T lymphocyte and NK cell granules. Following cell stimulation, GB induces apoptosis in the target cell (110 stimulations, so any single-cell assay should involve an activation step or be designed to probe otherwise activated cells. TNF-α can be produced in large copy numbers (>10 6 per cell within a 6-h period) and relatively quickly (10 per second). However, often only 10% of the total cell population will produce significant amounts of this protein. This low fraction of secretors may be associated with the relationship of the individual cells to their positions in the cell cycle (34) , the stochastic nature of biology, the prior history of the cells, etc. The low fraction of protein-producing cells is just one of the many factors that illustrate the need to assay statistically significant numbers of cells. Such statistics are straightforward for flow cytometry but must be specifically designed into any microfluidics platform. Figure 1 provides one-dimensional scatter plots showing how the average level and variance of a panel of secreted proteins, including TNF-α, differs among five immunotherapy cancer patients. These data were collected on a single-cell barcode chip (SCBC) (see Section 4) and illustrate the value of absolute calibrations. Those calibrations permit comparisons across different proteins and patients in this figure but also across time points, drug treatments, etc. Such calibrations are tough to do using flow cytometry. They rely on the availability of standard proteins and as such should also be interpreted with some caution. For example, proteins from a primary source may have different posttranslational modifications relative to the standard protein, and this can influence assay sensitivity.
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Figure 1
Scatter plots of the copy numbers per cell of three cytokines and CCL-4 assayed from single tumor antigen-specific CD4 + and CD8 + T cells collected from five cancer patients participating in an immunotherapy trial. Each dot is a single-cell assay. The measurement error is approximately 10%, and thus the distribution of protein levels reflects immune system heterogeneity which, for a given patient and by this metric, can span many orders of magnitude. Absolute calibrations were done with commercially available standard proteins. These data were collected and processed according to protocols outlined in Reference 28. Abbreviations: CCL, chemokine C-C motif ligand; CD, cluster of differentiation; IFN, interferon; TNF, tumor necrosis factor.
GB is secreted by certain immune cell phenotypes for cell killing functions. GB is not always commercially available (such is the case for many proteins), and this can preclude assay calibration. However, one can estimate the statistical variance of the abundance distribution across a relevant cell population if the immunoassay signal levels are in the linear regime. For a fluorescence assay, that is the range within a log-log plot of the measured fluorescence versus concentration that yields a straight line. The variance in protein abundance across many otherwise identical single cells will typically be high for almost any functional protein (Figure 1 ), but the details of that variance, and how it changes in response to some perturbation, contains biological information (see Section 5) . For a protein such as GB, most activated cells will not secrete GB at levels much above baseline, but the cells that are active secretors can be extremely active-effectively producing a bimodal population of secretors and nonsecretors.
The third protein in Table 1 is an activated (phosphorylated) membrane receptor kinase, p-EGFR, and the fourth is an activated cytoplasmic phosphokinase, p-ERK. Such kinases can typically be phosphorylated at any number of sites-not all of which significantly increase enzyme activity. Monoclonal antibodies that exhibit avidity for specific phosphorylated residues of specific proteins are used for detecting activated (and thus functional) kinases in both single-cell and bulk assays. The average number of copies of p-EGFR per cell (for model brain cancer cells) is approximately 2,000. Of course, if the cells are fixed, made permeable, and then antibody-stained for the presence of these proteins, 2,000 copies within a single cell is a relatively high concentration (micromolar order) (22, 35, 36) . However, if the cell contents are spilled out into microchambers with volumes in the 0.1-1-nL range, 2,000 protein copies translates into a 3-30-picoM concentration, which can push the limits of many fluorescent enzyme-linked immunosorbent assays (ELISAs). This highlights the need for strict attention to assay conditions. It isn't just about the antibodies! Surface chemistry also plays important roles. Phosphoproteins, such as p-EGFR and p-ERK, can be parts of the same intracellular signaling network. For example, activation of EGFR (to form p-EGFR) can, in turn, lead to ERK phosphorylation. Thus, ERK is called a downstream effector of EGFR. The implication is that the abundance of p-ERK within a cell will be positively influenced by the abundance of p-EGFR. Quantifying such protein relationships is an important piece of what is captured in a multiplexed single-cell functional proteomics assay.
The last protein, VEGF, is a secreted growth factor and a ligand for the VEGF receptor (VEGFR). It is associated with normal tissue function, but it is also associated with promoting angiogenesis in many solid tumors. From a detection standpoint, VEGF is similar to TNF-α, although, in hypoxic tumors, its production is often associated with the transcription factor hypoxia inducible factor (37) . Thus, for certain single-cell studies, it may be desirable to simultaneously monitor VEGF secretion levels and phosphoprotein signaling pathways. This highlights the interesting challenge of monitoring multiple classes of proteins (secreted, cytoplasmic, membrane) from the same single cells.
HISTORY OF NON-MICROCHIP SINGLE-CELL PROTEOMICS TOOLS
Single-cell proteomics methods have evolved over more than 50 years, dating back to the invention of the Coulter counter (38) , which evolved into the first cytometers (39) . The emergence of lasers, photon detectors, high-speed electronics, bioconjugation chemistries, and dye molecules fed into the development of fluorescence flow cytometry (FFC) (40) , fluorescence-activated cell sorting (FACS) (41) , and ELISpot (21) . Most recently, mass spectrometry advances have been harnessed for the development of mass cytometry (42) . Excepting ELISpot, the dominant applications of these tools have been for sorting or enumerating cellular phenotypes based on measurements of surface marker (membrane) proteins. Intracellular staining (ICS) techniques have opened FFC and mass cytometry up to the analysis of at least a few cytoplasmic functional proteins per cell. Each of these techniques has strongly influenced the development and/or the specific applications of the more recent microchip tools.
The Enzyme-Linked Immunosorbent Spot Method
ELISpot intrinsically assays for functional proteins (43) . The cells of interest (typically immune cells) are localized on a plate using surface-bound capture antibodies against specific cell surface markers. That surface is also coated with capture antibodies against specific secreted proteins. When the bound cells secrete proteins, fluorophore-labeled secondary antibodies are employed to bind to those captured proteins and provide a readout. By spatially correlating fluorescent spots with the locations of attached cells, the fraction of cells that are active secretors is recorded.
ELISpot assays are colorimetrically limited to the detection of approximately three proteins, but even with this limitation, ELISpot assays have been broadly used for monitoring immune system activation, most commonly by monitoring IFN-γ release (see, e.g., 44, 45) . However, other functions, such as cell-mediated cytotoxicity, can be tracked via ELISpot assays of GB and other cytotoxic granules (46) . ELISpot assays have provided several important lessons. First, secreted proteins from single cells may be readily detected with standard, sandwich-type ELISAs (47, 48) . Second, well-defined immune cell phenotypes can be functionally heterogeneous. Third, ELISpot assays begin to hint at the importance of immune cell function, relative to immune cell population abundance, in terms of understanding various disease processes.
Multicolor Fluorescence Flow Cytometry, Fluorescence-Activated Cell Sorting, and Mass Cytometry
FFC and FACS are the dominant workhorses for single-cell proteomics. They bring a reasonably high level of multiplexing. Measurements of 6-10 simultaneous parameters per cell are practical, and analysis of up to 19 or so parameters is possible with highly specialized equipment (49) . In this parlance, two parameters are associated with light scatter (forward and side) for discriminating between broadly different cell types (e.g., monocytes and platelets). The rest of the parameters are colorimetric, typically associated with different membrane proteins that are assayed using fluorophore-labeled antibodies. A triumph of modern biology has been the identification of cell surface markers that allow, by FACS, the enumeration and sorting of specific cellular phenotypes from blood or tissues. For example, a cytotoxic T cell is defined by the cell surface markers cluster of differentiation (CD)3, CD45, and CD8, with additional markers specifying the antigen specificity of the T-cell receptor (TCR) or providing further phenotypic classification, such as effector memory (50) . Mass cytometry, which was recently developed by Nolan's (42) group, extends the concept of FFC to a substantially higher level of multiplexing through the use of antibodies that are tagged with mass labels, rather than fluorophore labels. Measurements of up to 34 parameters at the single-cell level (binding of 31 antibodies, cell viability, DNA content, and relative cell size) (42) have been reported. The power of flow cytometry tools to sort specific cell types and to even help define immune cell differentiation (42, (49) (50) (51) has strongly influenced our basic picture of the immune system and how it functions in response to specific threats. Not coincidentally, immune cell biology has provided an important scientific driver for the development of microchip-based single-cell proteomics.
Protein cell surface markers permit the sorting of cellular phenotypes from broad populations, but analyzing the functional performance of those phenotypes requires assays of functional proteins. For immune cell functions, these are normally secreted proteins that mediate the tasks of target killing (GB), self-renewal [interleukin (IL)-2 for T cells], recruitment of other immune cell types, inflammation (IL-6), and immune system regulation (IL-10), etc. The relative levels of a few (typically two to five) of these proteins may be monitored through the use of ICS FFC (52, 53) . ICS FFC involves first blocking protein secretion and then fixing and making permeable the cells to allow for perfusion of antibody-labeled dyes. Although the blocking of protein secretion is a significant perturbation, much has been learned using ICS FFC. Examples include an understanding of the influence of pathogens toward steering functional diversity in phenotypically defined populations, as well as the importance of the specific nature of that functional diversity in immune responses to specific threats. Using similar cell staining protocols (54, 55) , ICS FFC has also been utilized to investigate the structure of phosphoprotein signaling pathways (36, 56, 57) . Those studies, which are almost exclusively from Nolan's (42) group, have been limited in number but highly informative. This highlights both the importance and difficulty of such investigations (58) .
Again, flow cytometry methods have helped define the opportunity for using single-cell functional proteomics to elucidate phosphoprotein signaling pathways, and this has influenced applications in corresponding microchip tools.
MICROCHIP-BASED SINGLE-CELL PROTEOMICS METHODS
These tools use either antibody staining of the investigated cells (similar to flow cytometry or ICS FFC) or surface-based immunoassays (similar to ELISpot) to measure proteins released from the cells. Within these two primary classes, there are further differentiators; some tools permit control over the chemical environment around each of the assayed cells, whereas others analyze cells that are physically, but not chemically, isolated. This is an important distinction, because control over the chemical environment surrounding a cell can yield a screening tool. Almost all of the tools permit the cells to be visualized using microscopy, and so certain parameters, such as cell size and cell morphology, are basically a given.
Tools Using Cellular Staining Assays
Early generation microfluidics-based single-cell proteomics platforms were essentially miniaturized versions of FACS tools. For example, Quake's (59) group developed a micro(μ)-FACS chip for separating green-fluorescent protein-expressing Escherichia coli cells from a mixed population of nonfluorescent and fluorescent bacteria. The design used programmable flow conditions to switch flow directions and permit the cell types to be directed into different collection chambers. An enabling conceptual advance was the earlier development of integrated microfluidics platforms that incorporated valves, mixers, microchannels, and microchambers onto the same microchip (1). This design flexibility has been adapted for some of the recent microchip proteomics platforms and has also been important in the development of tools for single-cell transcriptome analysis (3). Other variations have emulated the concepts of ICS FFC. Sun et al. (22) utilized multicolor analysis of fluorescent antibody-labeled cytoplasmic proteins to assay for six parameters from single cells (binding of four antibodies and cell size and DNA content) from several human brain tumor biopsies. Using fixed and permeable cells, they stained for the proteins EGFR, p-Akt (protein kinase B), p-S6k, and phosphatase and tensin homolog. These proteins are associated with the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (mTOR) signaling pathway that is hyperactivated in many cancers, including many brain cancers. This type of analysis requires much smaller sample sizes than are needed for flow cytometry, and the microchip platforms are also relatively inexpensive. Gerdes et al. (60) reported on a sequential staining procedure of formalin-fixed, paraffin-embedded tissues that permitted a high level (∼60 parameters) of multiplexing in what was effectively an advanced immunohistochemical staining approach that permitted some analysis at the single-cell level.
Virtually all other microfluidics single-cell proteomics tools utilizing cellular staining also separate the cells prior to analysis. One set of platforms, called cell arrays (19, 35, 61) 
detecting the enzyme NAD(P)H oxidase from single cells, and applied it toward measurements of single-cell enzyme kinetics for specific biomolecular processes. Cell array experiments typically allow on the order of 10 2 single-cell assays. Microdroplets (63) provide a related approach but one that permits control over the microenvironment surrounding each cell (18) . To date, there is not much literature in this area, although, with additional development, the concept might evolve into a viable screening approach. Control over the local chemical environment surrounding each cell is a distinguishing characteristic, because it can permit experiments that are hard to envision with flow cytometry or ELISpot. Microdroplets also permit assays on quantized cell populations and, through calibration with fluorescently labeled beads, microdroplet immunoassays can yield absolute quantitation of protein copy numbers (64) . Such calibrated assays, however, have not been applied to single cells but only to very small volumes of cell lysate.
4.1.1. Cell staining platforms: looking to the future. Those microchip platforms that rely on cell staining typically assay for one or two proteins per cell, although this limitation is not fundamental. Multicolor excitation and imaging techniques, coupled with modern dyes, should permit higher levels of multiplexing; however, they would also add much of the expense and sophistication of multicolor FFC but without the benefit of cell sorting. A more attractive option might be to use the imaging access afforded by these microchip tools to integrate super resolution imaging (65) with a conceptual extension of optical barcodes (66) . For the barcoding, an antibody would be labeled with a long ssDNA oligomer. That DNA, in turn, is hybridized with shortchain, complementary ssDNA oligomers to which dyes are attached. Super resolution imaging can permit the spatial resolution of dye labels. Thus, with n colors and p dye positions, one can generate sufficient barcodes to detect n p different proteins. This concept could rapidly yield multiplexing numbers that approach the size of the proteome. Although such an experiment is not currently practical, it provides at least a starting point for discussions regarding meeting the grand challenge of measuring the entire proteome within a single cell.
Tools Using Surface-Based Immunoassays
Tools using surface-based immunoassays are conceptually similar to ELISpot but have capabilities that can in many ways surpass those of cytometry tools. Separating protein assays from the cell implies that individual proteins can be spatially, rather than colorimetrically, identified, and that sandwich ELISA-type assays can be used. Of course, cell staining of proteins still can be simultaneously carried out. The result is a significantly higher level of multiplexing and, for some proteins, absolute quantitation. Second, intracellular, membrane, and secreted proteins may be assayed from the same single cell. Third, the chambers in which the cells are isolated can potentially accommodate multiple cells and/or cell types, thus permitting measurements of cellular interactions. Finally, these platforms allow the integration of functional assays (e.g., cell motility) with protein assays. In this class of platforms, only two base technologies-the microengraving technique from Love's group and our own SCBCs-have been reported, but both have been widely applied. We discuss the microengraving platforms first. Those proteins are assayed using sandwich ELISAs, and up to three secreted proteins are simultaneously detected using colorimetric discrimination. Thus, the approach is similar to ELISpot but with a few important distinctions. Much higher statistics are achievable, the cells are chemically isolated, and the microengraved substrate can be replaced in situ. Replaceable substrates enable single-cell kinetic studies (67) . Substrate removal also allows access to specific cells, identified from the proteomics assays, for subsequent analysis or culture formation (68) . Both of these advantages are very hard to replicate using flow cytometry tools. An additional advantage of the microengraving platform is that it can be modified for PCR-based detection of a few transcripts at the single-cell level (69) , although the combination of proteins and transcripts from the same single cells, using microengraved platforms, has not yet been reported. Figure 3 illustrates a microengraving experiment designed to detect antibody-secreting B cells collected from specific locations from a healthy mouse or a mouse model of the autoimmune disorder known as Sjögren's syndrome (68) . B cells are analyzed, using the microengraved slide, for their production of antibodies and for the specificity of those antibodies against specific antigens. If certain of the B cells exhibit particularly interesting behavior, they can be recovered for further culture or analysis.
Single-cell barcode chips.
SCBCs are versatile and information-rich tools in which single cells, or defined numbers of cells, are isolated within microchambers that each contain a manyelement antibody array (the barcode). A few hundred to 10 4 individual microchambers are included within a single microchip. Depending on the application, microchamber volumes are between 0.1 and 2 nL (26, 28) , and microchamber design and operation protocols can permit sandwich-type ELISA immunoassays of cytoplasmic, secreted, or membrane proteins with a measurement error of ∼10% for a given protein level (29) .
Standard protocols may be used for microchip construction, but the patterning approach for the antibody barcode has unique constraints. The barcode is the enabling SCBC technology; as such, we discuss it in some detail here. Because of the instability of antibodies for long-term storage, or toward microchip processing conditions, the barcodes are initially patterned as ssDNA barcodes, with each barcode stripe having a unique ssDNA label. A cocktail of antibodies labeled with complementary ssDNA oligomers is used to convert the DNA barcode into an antibody barcode, just prior to running an assay (70) (71) (72) . The microchamber surface area available for a typical 20-element barcode is between 150 × 150 μm 2 and 1,000 × 150 μm 2 , implying each array element needs to be approximately 10-20 μm wide, at a 20-40-μm pitch. Such dimensions may be read with a standard array scanner (73) but are beyond the resolution of standard spotting tools (74) . Molecular patterning tools that can approach these dimensions include molded elastomer stamping (75, 76) , dip pen lithography (77) , and microfluidic flow patterning (78) . Of these choices, stamping does not permit the required level of multiplexing, whereas dip pen does not yield a surface coverage sufficient for stable and sensitive assays. Thus, we have developed microfluidic www.annualreviews.org • Single-Cell Functional Proteomicsflow patterning into the method of choice for SCBCs, including even building robotics systems to automate the task (79) . In Figure 4 we provide data showing the influence of various barcoding surface chemistries on assay sensitivity, some of which are described in Reference 20. Details of the ssDNA oligomers and antibody pairs used in SCBCs can be found in the supplementary materials of numerous publications (2, 28, 30, 80) . The flow patterning approach described in Figure 4 can be modified for doubling the density of the antibody arrays (26, 81) . Figure 5 depicts an SCBC microchamber designed for assaying phosphoprotein signaling pathways from single cells, along with representative data from such an assay. A full SCBC data set may contain 20 or more assayed proteins (R. Fan, unpublished data) and is recorded as a table. Each row corresponds to a microchamber address, and the columns contain the numbers and locations (or other descriptors) of cells within that microchamber, as well as the assayed levels of the individual proteins.
BIOLOGICAL AND BIOMEDICAL APPLICATIONS

Immunology and Immune Monitoring
Because of the variety of potential pathogen targets, cellular immunity is functionally heterogeneous, which is a characteristic uniquely quantitated at the single-cell level. Many efforts to capture this heterogeneity have used ICS FFC. An example is the work of Betts et al. (82) , who measured five functions (degranulation and levels of IFN-γ, macrophage inflammatory protein 1b, TNF-α, and IL-2) from single HIV-specific CD8 + T cells collected from chronically HIV-infected individuals and showed that the number functions (the polyfunctionality) were inversely correlated with viral load in those patients. Newell et al. (51) used ICS mass cytometry to assay 17 membrane protein markers, 6 intracellular cytokines, and 2 cytotoxic granules from stimulated CD8 + T cells from healthy patients. They found an almost combinatorial distribution of cytokine secretion profiles across the individual cells, but there were distinct niches occupied by virus specific cells.
Microfluidic platforms have also been used to address the question of functional heterogeneity in cellular immunity. Ma and coworkers (28, 80) reported on the longitudinal monitoring of patients undergoing TCR-engineered adoptive cell transfer (ACT) cancer therapy (83) . This cell-based immunotherapy was for the treatment of metastatic melanoma. SCBCs were used to compare the functional diversity of tumor antigen (MART-1)-specific CD8 + T cells collected from the blood of melanoma cancer patients with CD8
+ T cells collected from healthy donors. They combined 19-plex SCBC functional (secreted) protein assays with 10-color FACS to measure the functional evolution of specific T-cell phenotypes at 5 to 10 time points over a 90-day trial. These measurements led to several conclusions. First, for a given patient and T-cell phenotype, if all single-cell data from all time points were coanalyzed, a level of functional coordination was resolved, meaning that the T cells could be loosely classified according to biological behaviors, such as antitumor or proinflammatory behaviors. Second, the most polyfunctional cells dominated the immune response: Roughly 10% of the cells of a given phenotype secreted five or more different proteins and, for any one of those proteins, those highly functional cells secreted, on average, 100-fold more protein copies than the less polyfunctional cells. Thus, for a given phenotype, 10% of the cells dominated the overall immune response by tenfold. This led to the defining of a polyfunctionality strength index. Interestingly, although the cellular population dynamics or phenotype changes (such as naïve or central memory) over the course of the trial did not yield clear clinical correlates, the polyfunctionality kinetics did correlate with clinical observations, providing feedback for potentially improving the ACT trial design. This collective work over the past decade has refined the notion that the quality of a T-cell immune response is best captured by the functional performance of the T cells, rather than by their quantity (84) . Most reported applications of the microengraving platform have also focused on immunology (25, 67, (85) (86) (87) (88) (89) . These investigations have emphasized types of experiments that are not tractable using the various cytometry methods. The first is the ability to replace, in situ, the microengraved slide that contains the immunoassays, thus permitting investigations of the kinetics of protein secretion (67, 89) from single activated T cells. Those studies resolve individual T cell secretion trajectories and have provided a higher resolution picture of T cell kinetics than can be captured by more traditional means (34, 90) . A second aspect of the microengraving studies has been to identify immune cells with interesting functional properties and then find ways to separate those cells for additional investigations (68, 88) . Those studies are particularly interesting from the point of view of identifying antigen-specific cells (e.g., B cells or T cells). Such cells, although often difficult to isolate, play important roles in immune responses (91) or in therapies that rely on encouraging or engineering (92) such responses against disease-specific antigens. The microengraving platform may provide a viable approach toward identifying and characterizing these rare cells.
Phosphoprotein Signaling Pathways
For many cancers, genomic surveys are revealing a landscape of altered signal transduction cascades that often cluster along a set of druggable core pathways. In fact, these pathways contain molecular targets for newer generations of cancer therapies (14) . However, the translation of genomic data into effective clinical treatments has been confounded because nongenetic cell-to-cell variability is profound in drug responses and resistance development. A recent editorial (93, p. 2) has pointed out that capturing the functional protein signaling networks may prove valuable for this purpose, because those signaling proteins, "not the genes per se, are responsible for the phenotypes of tumors and for the emergence of therapeutic resistance." Single-cell proteomics provides the most direct approach for elucidating protein signaling network structure and coordination, and information from such measurements emerges at many levels. First, the spread (variance) in copy numbers of a given protein, as measured across each of many otherwise identical single cells (see Figure 1 or Figure 5d ), can represent the functional heterogeneity of that protein. Population heterogeneity can arise from factors such as the stochastic nature of intracellular events (94) controlled by low-copy-number transcription factors (95) or through cell-cell interactions (95, 96) . The net result may be high-amplitude fluctuations at the single-cell level but stability across a population (97) . In other words, the population is stable exactly because it is heterogeneous (consider, for example, the robust nature of a diverse economy). This concept can be quantified using statistical physics models. Thus, fluctuation measurements can capture cellular heterogeneity, while simultaneously providing a measure of the stability of the organelle, tumor, etc., that is comprised of those cells and providing a bridge to statistical physics models with predictive capacity. This approach contrasts with traditional biology thinking, which might seek to classify the population into functional phenotypes. Such thinking discards the heterogeneity of the system in favor of a more streamlined (but ultimately nonpredictive) description.
A second level of information involves protein-protein correlations (Figure 5e ). Correlations and anticorrelations can imply activating and inhibitory interactions. This means that measurements with higher multiplexing capacity will capture larger numbers of such interactions and thus increasingly resolve the associated protein signaling network (29, 57) . The use of physicochemical laws to predict biological behaviors based on single-cell proteomics assays has been studied by Shin et al. (98) to investigate (and predict) how stimulated macrophage cells respond to various perturbations. More sophisticated, but related, approaches were applied to study the influence of hypoxia (reduced O 2 partial pressure) on glioblastoma multiforme tumors (30) . For that study, highly specific and surprising predictions of hypoxia-dependent therapy resistance were made regarding the use of mTOR inhibitors to treat both cell lines and tumor models. Those predictions were verified.
Assays in which measurements of both cellular function and functional protein levels are executed from the same single cells represent experiments that are unique to the microchip platforms. Lu et al. (24) , using a platform that was more or less an SCBC-microengraving hybrid, investigated a panel of 14 different secreted proteins, as well as motility assays, on model cancer cells, with additional extensions to primary cells derived from patient brain tumors. They identified three specific secreted proteins that correlated with cell motility.
Cell-Cell Interactions
A unique aspect of microchip platforms is that they can permit investigations of quantized cell populations. Such explorations have focused, at varying levels of resolution, on the inhibitory or activating nature of intercellular interactions and have combined protein assays with functional observations (99) (100) (101) (102) . A recent study (26) correlated the levels of a panel of phospho-and secreted signaling proteins in model glioblastoma multiforme (brain cancer) cells, with cell-cell distances in two-cell assays. The work revealed that a detailed knowledge of pairwise cell interaction functions could be used to predict specific properties of larger cell populations. Such experiments again draw from concepts derived from statistical physics (103) and may eventually allow complex phenomena within tissue microenvironments to be understood.
Although not exactly single-cell work, Shao et al. (104) reported on protein typing of individual circulating microvesicles using a novel microchip/nuclear magnetic resonance system. Microvesicles (105) are significantly smaller than the cells that they originate from and can provide a medium for cell-cell communication (106) but may also provide a rich source of circulating tumor markers. This can be especially informative for intracranial tumors, which do not shed cells into the circulatory system. Yamanaka et al. (27) utilized a microengraved platform to investigate the interactions between lymphocytes known as natural killer (NK) cells and target cells. NK cells can recognize and kill certain cells (such as viral infected cells) without the need for antigen recognition. The workers found that NK cells operate independently and promptly when lysing a single target cell. They also found that IFN-γ secretion correlates with low motility for NK cells that have contacted a target cell. These types of cell-cell interaction studies may eventually lead to an improved understanding of the functional heterogeneity of the immune system.
LOOKING TO THE FUTURE
Powerful tools such as mass cytometry have appeared over the past few years, but new classes of microchips for single-cell functional proteomics have also emerged with distinct and powerful advantages that are just now being explored. With such a rapidly developing field, looking into the future is tricky. One approach is to consider the low-hanging fruit, the technology bottlenecks, and the biological and clinical drivers that are pushing the field forward. For example, all the pieces currently exist to permit highly multiplexed transcriptome and proteome analyses of the same primary single cells; as such, this is a low-hanging fruit. The rapid advances of immunotherapy will likely push the development of such multilevel assays toward those that can identify and clone the very rare cells that produce particularly interesting antibodies or TCRs. Another clinical driver is the increase in the development and use of targeted cancer therapies, coupled with the confounding modest performance of those drugs that is often seen in the clinic. Bridging that gap will require resolving, at an unprecedented level, the structure of the phosphoprotein signaling networks that are targeted by those therapies. A technical bottleneck involves the level of multiplexing achievable using current approaches. Both cytometry and microchip tools likely reach a limit between 50 and 100 proteins per cell. Even beating this limit by a factor of two or three would still represent sampling only a tiny part of the proteome. This limit arises because of the reliance on antibody-based detection schemes. Beating this limit will require either (a) a protein capture agent technology that is the equivalent of very cheap, robust, and very high performing monoclonal antibodies or antibody-equivalents or (b) a discovery approach, such as mass spectrometry, for single-cell proteomics.
Finally, an increased emphasis on accurate and quantitative measurements will clearly push the field forward, simply because of the transportability of such measurements for comparisons across cell lines, patient samples, etc. This is a lesson drawn from the current revolution in mass spectrometry proteomics. Focused proteomics tools such as multiple reaction monitoring (107) , coupled with the existence of the human peptide atlas (108) , have brought mass spectrometry to the point where it is now being developed as a truly quantitative clinical diagnostics tool for measuring panels of protein biomarkers. The strong emphasis on quantitative and accurate measurements highlights the role of analytical chemistry for this field.
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